Adaptimmune Therapeutics Q1 2023 Earnings Report $0.56 -0.02 (-3.45%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Adaptimmune Therapeutics EPS ResultsActual EPS$0.01Consensus EPS -$0.19Beat/MissBeat by +$0.20One Year Ago EPSN/AAdaptimmune Therapeutics Revenue ResultsActual Revenue$47.60 millionExpected Revenue$7.70 millionBeat/MissBeat by +$39.90 millionYoY Revenue GrowthN/AAdaptimmune Therapeutics Announcement DetailsQuarterQ1 2023Date5/12/2023TimeN/AConference Call ResourcesPress ReleaseADAP Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Adaptimmune Therapeutics Earnings HeadlinesAdaptimmune Therapeutics (NASDAQ:ADAP) and Neumora Therapeutics (NASDAQ:NMRA) Head to Head ReviewFebruary 15, 2025 | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)February 11, 2025 | markets.businessinsider.comWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."February 22, 2025 | Brownstone Research (Ad)Guggenheim Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)January 30, 2025 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Adaptimmune Therapeutics (ADAP)January 23, 2025 | markets.businessinsider.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years agoJanuary 22, 2025 | uk.finance.yahoo.comSee More Adaptimmune Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptimmune Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your email. Email Address About Adaptimmune TherapeuticsAdaptimmune Therapeutics (NASDAQ:ADAP), a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.View Adaptimmune Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
